A 17-year experience of abobotulinumtoxinA in cervical dystonia

International Journal of Neuroscience

Volumn 122, Issue 7, 2012, Pages 354-357

  Vivancos Matellano, Francisco ^a   Ybot Gorrin, Isabel ^a   Diez Tejedor, Exuperio ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

abobotulinumtoxinA; cervical dystonia; chart review; Dysport; long term

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CERVICAL DYSTONIA; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ELECTROMYOGRAPHY; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXINS, TYPE A; CHILD; ELECTROMYOGRAPHY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TORTICOLLIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862225015     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.665971     Document Type: Article

References (13)

1. Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007;13:411-6. (Pubitemid 47454719)
2. Brashear A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics. 2009;3:1-7.
3. Crowner BE. Cervical dystonia: Disease profile and clinical management. Phys Ther. 2007;87:1511-26. (Pubitemid 350074386)
4. Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry. 2002;72:608-14. (Pubitemid 34462815)
5. Cloud LJ, Jinnah HA. Treatment strategies for dystonia. Expert Opin Pharmacother. 2010;11:5-15.
6. Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5-18.
7. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20:783-91. (Pubitemid 41227144)
8. Wissel J, Kanovsky P, Ruzicka E, Bares M, Hortova H, Streitova H, et al. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: Results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol. 2001;248:1073-8. (Pubitemid 34134544)
9. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, et al.What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study usingDysport.GermanDystonia Study Group. J Neurol Neurosurg Psychiatry. 1998;64:13-7. (Pubitemid 28156531)
10. Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16:316-23.
11. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res. 2009;31:463-6.
12. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Sub-committee of the American Academy of Neurology. Neurology. 2008;70:1699-706. (Pubitemid 351644138)
13. Camargo CH, TeiveHA, Becker N, BaranMH, Scola RH,Werneck LC. Cervical dystonia: Clinical and therapeutic features in 85 patients. Arq Neuropsiquiatr. 2008;66:15-21. (Pubitemid 351520710)